ReviewDrugs2005
Pegaptanib: in exudative age-related macular degeneration.
Review in Drugs, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Interventions for age-related visual problems in patients with stroke.The Cochrane database of systematic reviews · 2012Pooled it
- Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration.The Cochrane database of systematic reviews · 2008Pooled it
- Aptamers in Osteosarcoma: New Paths for Diagnosis and Treatment.Anti-cancer agents in medicinal chemistry · 2026Review
- The 20th Anniversary of Pegaptanib (MacugenTM), the First Approved Aptamer Medicine: History, Recent Advances and Future Prospects of Aptamers in Therapy.Pharmaceutics · 2025Review
- Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.Signal transduction and targeted therapy · 2025Review
- Aptamers: precision tools for diagnosing and treating infectious diseases.Frontiers in cellular and infection microbiology · 2024Review
- Non-coding RNAs in the pathophysiology of heart failure with preserved ejection fraction.Frontiers in cardiovascular medicine · 2023Review
- Small non-coding RNA therapeutics for cardiovascular disease.European heart journal · 2022Review
- A perspective on oligonucleotide therapy: Approaches to patient customization.Frontiers in pharmacology · 2022Review
- Aptamer-siRNA chimera and gold nanoparticle modified collagen membrane for the treatment of malignant pleural effusion.Frontiers in bioengineering and biotechnology · 2022Article
- The infinite possibilities of RNA therapeutics.Journal of industrial microbiology & biotechnology · 2021Article
- [Preparation of dual-functional composite magnetic nanomaterials modified with different metals/aptamers and their performance in exosome enrichment].Se pu = Chinese journal of chromatography · 2021Article
- Synthetic Approaches for Copolymers Containing Nucleic Acids and Analogues: Challenges and Opportunities.Polymer chemistry · 2021Article
- Recent Progress and Opportunities for Nucleic Acid Aptamers.Life (Basel, Switzerland) · 2021Review
- Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody).International journal of molecular sciences · 2020Article
- DNA aptamers against the DUX4 protein reveal novel therapeutic implications for FSHD.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
- Aptamer Therapeutics in Cancer: Current and Future.Cancers · 2018Review
- Aptamers Selected for Recognizing Amyloid β-Protein-A Case for Cautious Optimism.International journal of molecular sciences · 2018Review
- An Aptamer-Based Probe for Molecular Subtyping of Breast Cancer.Theranostics · 2018Article
- Aptamer selection and applications for breast cancer diagnostics and therapy.Journal of nanobiotechnology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pegaptanib, an aptamer, is an antagonist of vascular endothelial growth factor that has shown efficacy in the treatment of patients with exudative age-related macular degeneration (AMD). In two randomised, double-masked trials in patients with exudative AMD (n=1208), the proportion of responders (those losing <15 letters of visual acuity) at 54 weeks was significantly higher in intravitreous pegaptanib 0.3 mg recipients than in those receiving sham injections (70% vs 55%; p<0.001). These trials were conducted concurrently and analysed as a single study; the treatments were given every 6 weeks for 48 weeks. The improvement in visual acuity with pegaptanib was maintained in a 1-year extension of these trials. Similar favourable results with pegaptanib 0.3 mg were seen in terms of the secondary efficacy endpoints (e.g. proportion of patients experiencing severe loss of visual acuity or legal blindness in the study eye). These vision-improving effects of pegaptanib were associated with beneficial angiographic effects. Intravitreous pegaptanib 0.3-3 mg was well tolerated with most ocular adverse events being mild-to-moderate and transient. Serious injection-related adverse events occurred in <or=1.3% of patients treated with pegaptanib. There were no systemic adverse events that could be definitely attributed to pegaptanib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.